ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Triple Negative Breast Cancer Clinical Trial

Official title:

Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate) for Patients With HER2-low Locally Advanced Unresectable / Metastatic Breast Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06224673
• Other study ID #: 237527
• Secondary ID: NCI-2024-00073
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 15, 2024
• Est. completion date: November 30, 2028

Study information

• Verified date: June 2024
• Source: University of California, San Francisco
• Contact: Amy Langdon
• Phone: (415) 353-7288
• Email: amy.deluca[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.

Description:

PRIMARY OBJECTIVES: I. To evaluate the objective response rate (ORR) of participants with HER2-low locally advanced unresectable/metastatic breast cancer on ARX788 monotherapy. SECONDARY OBJECTIVES: I. To evaluate the efficacy of ARX788 monotherapy in participants with HER2-low locally advanced unresectable / metastatic breast cancer as measured by duration of response (DOR), best overall response (BOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). II. To evaluate the safety of ARX788 monotherapy in participants with HER2-low locally advanced unresectable / metastatic breast cancer (MBC). OUTLINE: EXPLORATORY OBJECTIVES: I. Biomarker analyses to evaluate association of efficacy measures with potential biomarkers (e.g., via assessment of circulating tumor deoxyribonucleic acid (ctDNA), single cell ribonucleic acid [RNA] sequencing, etc.). II. Patient-reported outcomes (PROs) of patients on ARX788 monotherapy. III. To determine the feasibility, tolerability, and efficacy of eye toxicity prevention strategy. OUTLINE: Participants receive ARX788 intravenously (IV) over 90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants also undergo computed tomography (CT), positron emission tomography (PET)/CT, and collection of blood samples throughout the study. After completion of study treatment, participants are followed up at 30 days and then every 3 months for 1 year.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 36
• Est. completion date: November 30, 2028
• Est. primary completion date: November 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female participants age 18 years or greater with ability to provide written informed consent for the study.
• Eastern Cooperative Oncology Group (ECOG) score of 0-2.
• Estimated life expectancy of at least at 6 months per investigator assessment.
• Ability to understand and the willingness to sign a written informed consent document.
• Pathologically documented HER2-low locally advanced unresectable or metastatic breast cancer. NOTE: human epidermal growth factor receptor 2 (HER2) low status determined by HER2 immunohistochemistry (IHC) 1+ or 2+ and no evidence of HER2 gene amplification by in situ hybridization (ISH)/fluorescence in situ hybridization (FISH), which can be documented from any tumor sample during the patient's cancer treatment history (early or metastatic disease).
• Cohort 1: Participants with hormone receptor positive (HR+)/HER2-low locally advanced unresectable or metastatic breast cancer. Hormone receptor positive status defined as estrogen receptor >= 10% and/or progesterone receptor = 10% and HER2 low.
• Cohort 2: Participants with triple negative breast cancer (TNBC), HER2-low locally advanced unresectable or metastatic breast cancer. Considered TNBC if estrogen receptor (ER) and progesterone receptor (PR) < 10% and HER2 low.
• Presence of at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. NOTE: Participant's with at least one measurable lytic bone lesion are eligible.
• Availability of tumor block or formalin-fixed paraffin-embedded (FFPE) tissue as 10 precut unstained slides will be collected for the HER2 status evaluation and biomarker analysis based on the most recent tumor tissue sample. NOTE: New pretreatment biopsy tissue is preferred as HER2 status may change, but a fresh biopsy is not required. The study team and investigator will make every attempt to get archival tissue. Participants who do not have archival or new tumor tissue available may be eligible after discussion with the study principal investigator (PI).
• Participants with stable and treated brain metastases are eligible if the participants

meet the following criteria:

• Must be at least one week out from stereotactic radiosurgery and four weeks out from whole brain radiation therapy without new or progressive neurologic symptoms.
• Must be stable on an equivalent prednisone dose of 10mg or less daily.
• Participants must have received at least one prior line of chemotherapy or ADC therapy for locally advanced unresectable or metastatic disease. NOTE: Prior checkpoint inhibitor therapy is allowed.
• Hemoglobin = 8 g/dL
• Absolute neutrophil count = 1.0 x 10^9/L
• Platelets = 100,000 x 10^9/L
• Total bilirubin = 1.5 x institutional upper limit of normal, unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) < 3 x institutional upper limit of normal. In participants with liver metastases, <= 5 x institutional upper limit of normal is allowed.
• Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) < 3 x institutional upper limit of normal. In participants with liver metastases, <=5 x institutional upper limit of normal is allowed.
• Creatinine = 1.5 x within institutional upper limit of normal OR creatinine clearance glomerular filtration rate (GFR) = 50 mL/min/1.73 m, calculated using the Cockcroft-Gault equation
• Adequate cardiac function as assessed by left ventricular ejection fraction = 50% or institutional lower limit of normal.
• Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy.
• Individuals with a history of hepatitis C virus (HCV) infection must have been treated without detectable HCV RNA.
• Participants must have recovered from all acute toxicities from prior therapies to = grade 1 or baseline (except for alopecia and neuropathy) per the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.
• Male or female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or total sexual abstinence during and after completion of the study for at least 8 months after the last dose of study drug. Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 8 months after the final study drug administration. Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 8 months after the final study drug administration.

Exclusion Criteria:

• Has a prior history of treatment with ARX-788 or auristatin analogues.
• Has a history of allergic reaction to any component of ARX788.
• Has exposure to any other investigational or commercial anti-cancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of study treatment. NOTE: Anti-hormonal therapy may be administered up to 7 days prior to the first dose of study treatment.
• Received localized palliative radiotherapy less than 7 days prior to the first dose of ARX788 or has current radiotherapy-induced toxicity of grade 2 or greater (excluding rash) based on NCI-CTCAE v 5.0.
• Prior or current history of interstitial lung disease (ILD), pneumonitis, or other clinically significant lung disease with the exception of disease that is directly attributable to the presence of lung metastases from their underlying cancer.
• Participants with significant treatment-related lung injury, defined as any of the

following:

• Any prior history of drug-induced immune-mediated pneumonitis.
• Prior history of radiation therapy to the chest of > 18 gray (Gy) with residual sequelae considered clinically significant by investigator assessment.
• Radiographic evidence of radiation fibrosis involving > 15% of the lung parenchyma associated with clinical symptoms.
• Has a history of keratitis, keratopathy, and/or active eye disease (excluding glaucoma).
• Has a diagnosis of leptomeningeal carcinomatosis. NOTE: Stable brain metastases are allowed.
• Has an active systemic or psychiatric illness that would impact the patient's ability to receive study therapy.
• Has an uncontrollable intercurrent illness, infection (including participants with active, symptomatic Coronavirus disease of 2019 (COVID-19) infections), or other conditions that could limit study compliance or interfere with study assessments.
• Has a history of an additional malignancy that is progressing or has required active treatment within the past 3 years. NOTE: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, and thyroid cancer not requiring cytotoxic agents that have undergone potentially curative therapy are not excluded.
• Participants who are pregnant or breastfeeding.
• Has an active, uncontrolled hepatitis B, hepatitis C, and/or human immunodeficiency virus (HIV) infection. Participants with adequately controlled hepatitis B, hepatitis C, and/or HIV are allowed. NOTE: HIV and hepatitis B and C testing are not required for screening. Testing will only be done if clinically indicated.

Related Conditions & MeSH terms

• Breast Neoplasms
• Carcinoma
• Hormone Receptor Positive Breast Carcinoma
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• ARX788
Given IV

Procedure:
• Computed Tomography (CT)
Undergo CT or Positron Emission Tomography(PET)/CT
• Biospecimen Collection
Undergo collection of blood samples

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
Laura Huppert, MD, BA	Ambrx, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	Objective response rate (ORR) is defined as the proportion of participants who experience complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR and corresponding two-sided exact 90% confidence intervals will be reported.	Up to 1 year
Secondary	Duration of response (DOR)	Duration of response (DOR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first, will be computed for participants with a BOR of CR or PR. Medians and corresponding two-sided 95% confidence intervals will be reported.	Up to 1 year
Secondary	Overall Best Response (BOR)	Best overall response (BOR) is defined as the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started).	Up to 1 year
Secondary	Disease Control Rate (DCR)	The Disease control rate (DCR) is defined as the sum of PR, CR and stable disease (SD) divided by the number of response evaluable participants All-Subjects-as-Treated(AsaT).	Up to 1 year
Secondary	Median Progression Free Survival (PFS)	Progression-free survival (PFS) is defined as the time between date of first dose of study therapy and date of progression or death, whichever occurs first, will be computed for response evaluable participants (AsaT). Medians and corresponding two-sided 95% confidence intervals will be reported.	Up to 2 years
Secondary	Median Overall Survival (OS)	Overall survival (OS) is defined as the amount of time that elapses between the initiation of therapy (Cycle 1, Day 1 (C1D1) and the time of death from any cause. Medians and corresponding two-sided 95% confidence intervals will be reported.	Up to 2 years
Secondary	Proportion of participants with treatment-emergent adverse events (AEs)	Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.	Up to 1 year